Nuvini Group Announces Reverse Stock Split

Nuvini Group Announces Reverse Stock Split GlobeNewswire October 02, 2025 NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading serial acquirer in the Latin American SaaS sector, today announced that its Board of Directors has approved a 10-to-1 reverse stock split of its common stock, […]

Canadian Investment Regulatory Organization Trade Resumption – BK.PR.A

Trading resumes in: Company: Canadian Banc Corp. TSX Symbol: BK.PR.A All Issues: No Resumption (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which

CTO Investors Have Opportunity to Lead CTO Realty Growth, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstCTO Realty Growth, Inc. (“CTO” or “the Company”) (NYSE: CTO) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstAltimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's

Premier Health Reports AMP Decision Regarding Subsidiaries in Quebec

(TSX-V:PHA), MONTRÉAL, Oct. 02, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Company” or “Premier Health“), a leading Canadian health tech company, today announced that its subsidiaries, Code Bleu, Placement Premier Soin, Premier Health Nordik and Solutions Nursing (the “Quebec Subsidiaries”), have been notified by the Autorite des marches publics (AMP)

Premier Health Reports AMP Decision Regarding Subsidiaries in Quebec

Premier Health Reports AMP Decision Regarding Subsidiaries in Quebec GlobeNewswire October 02, 2025 MONTRÉAL, Oct. 02, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Company” or “Premier Health“), a leading Canadian health tech company, today announced that its subsidiaries, Code Bleu, Placement Premier Soin, Premier Health Nordik and Solutions Nursing (the

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

(NASDAQ:QNTM),(CNSX:QNTM.CN),(Boerse Frankfurt – Freiverkehr:0K91),(CNSX:QNTM), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial GlobeNewswire October 02, 2025 TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company“), a biopharmaceutical company dedicated

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

(NASDAQ:STTK), AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion

Scroll to Top